Shasun Pharmaceuticals Limited

Shasun Pharmaceuticals Limited is a Chennai-based company specializing in the development and manufacturing of active pharmaceutical ingredients (APIs) and specialty chemicals for the healthcare sector. Founded in 1976 in Chennai, India, Shasun Pharmaceuticals focuses on producing APIs and specialty chemicals. The company underwent a significant change in ownership when SeQuent Scientific acquired a minority stake for INR 1. 165 billion in April 2014.

Shasun operates globally, with an emphasis on quality and regulatory compliance. The founder's previous ventures are not disclosed, and there is no mention of subsidiaries or parent companies. Shasun offers a wide array of pharmaceutical products, primarily focusing on APIs and specialty chemicals. The company specializes in developing high-quality APIs for therapeutic areas such as cardiovascular, anti-diabetic, and anti-infective treatments.

Their products meet stringent regulatory standards and are marketed internationally to pharmaceutical companies and healthcare providers, ensuring access to essential medications across the United States, Europe, and Asia. Shasun aims to continuously innovate and expand its product offerings to meet the evolving healthcare needs. In 2015, Shasun Pharmaceuticals reported a revenue of INR 215,450,225. 8 and an EBITDA of INR 21,063,664.

6. The company's revenue model relies on business-to-business transactions with pharmaceutical manufacturers, established through long-term partnerships, fostering stable revenue streams. The pricing structure is tailored to the complexity of production and client specifications, with flagship products contributing significantly to overall sales, backed by a commitment to quality and regulatory compliance. Looking ahead, Shasun Pharmaceuticals plans to launch upcoming products in various therapeutic areas, although specific release dates are not provided.

The company is targeting expansion into new markets, with a focus on growing its presence in Asia and Europe by the end of 2025. The funding from the recent Trade Sale, amounting to INR 1. 165 billion, will support these initiatives, allowing Shasun to enhance its product portfolio and increase market reach.